Home Corporate Overview Human Medicine Veterinary Medicine Publications News Investor Relations Careers Contact Accueil PHARMACEUTICAL COMPANY Our vision is to continuously deliver innovative therapeutic drugs that will significantly improve the health of patients. LATEST NEWS Filing of masitinib in the treatment of amyotrophic lateral sclerosis to the European Medicine Agency (EMA) 29/09/2016 - The review process started on 12 September 2016 First half of 2016 results 31/08/2016 - AB Science reports its revenues for the first half of 2016 and provides an update on its activities Masitinib Receives from EMA Orphan Drug Designation in the European Union for Amyotrophic Lateral Sclerosis (ALS) 08/08/2016 - The EMA Committee for Orphan Medicinal Products (COMP) granted orphan drug status to Masitinib for the treatment of ALS Action plan following warning letter has been validated by FDA 14/07/2016 - AB Science announces the announces the publication of preclinical study results with masitinib in amyotrophic lateral sclerosis (ALS) 11/07/2016 - This publication validated the plausibility of masitinib's primary mechanism of action PRODUCT INQUIRIES © COPYRIGHT AB SCIENCES. ALL RIGHTS RESERVED. I MASIVET® I KINAVET® I LEGAL NOTICE I DESIGN : AGENCE K2

Home Corporate Overview Human Medicine Veterinary Medicine Publications News Investor Relations Careers Contact Accueil Basic Research Mast Cells as a Target Human Medicine Veterinary Medicine Full scientific book available on demand : contact@ab-cience.com Comparative analysis of the kinase selectivity profile of masitinib versus other TKIs 25/07/2014 - The knowledge of the selectivity of PKIs is a critical point for the development of optimal safe and well tolerated [...] PLoS ONE 2009 Dubreuil - MASITINIB A POTENT c-KIT INHIBITOR 30/09/2009 - Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT © COPYRIGHT AB SCIENCES. ALL RIGHTS RESERVED. I MASIVET® I KINAVET® I LEGAL NOTICE I DESIGN : AGENCE K2